Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more
Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.85 Billion CNY
Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has total liabilities worth CN¥1.85 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tianjin Tianyao Pharmaceuticals Co Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Tianyao Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Almonty Industries Inc
OTCQX:ALMTF
|
USA | $305.14 Million |
|
Formycon AG
XETRA:FYB
|
Germany | €334.23 Million |
|
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
|
China | CN¥305.98 Million |
|
Friend Co Ltd
SHG:605050
|
China | CN¥4.13 Billion |
|
Guangdong Chant Group Inc
SHE:002616
|
China | CN¥7.51 Billion |
|
Yatharth Hospital & Trauma Care Services Limited
NSE:YATHARTH
|
India | ₹-16.37 Billion |
|
ZJMI Environmental Energy Co. Ltd.
SHG:603071
|
China | CN¥5.60 Billion |
|
Chorus Aviation Inc
PINK:CHRRF
|
USA | $802.61 Million |
Liability Composition Analysis (1998–2024)
This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Tianyao Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Tianyao Pharmaceuticals Co Ltd (1998–2024)
The table below shows the annual total liabilities of Tianjin Tianyao Pharmaceuticals Co Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion | -24.14% |
| 2023-12-31 | CN¥2.39 Billion | -17.53% |
| 2022-12-31 | CN¥2.90 Billion | +14.58% |
| 2021-12-31 | CN¥2.53 Billion | +5.19% |
| 2020-12-31 | CN¥2.40 Billion | +41.78% |
| 2019-12-31 | CN¥1.70 Billion | +11.65% |
| 2018-12-31 | CN¥1.52 Billion | +31.59% |
| 2017-12-31 | CN¥1.15 Billion | +125.69% |
| 2016-12-31 | CN¥511.21 Million | -12.53% |
| 2015-12-31 | CN¥584.42 Million | +16.57% |
| 2014-12-31 | CN¥501.34 Million | -36.19% |
| 2013-12-31 | CN¥785.64 Million | +8.50% |
| 2012-12-31 | CN¥724.13 Million | -0.79% |
| 2011-12-31 | CN¥729.86 Million | -43.34% |
| 2010-12-31 | CN¥1.29 Billion | +20.67% |
| 2009-12-31 | CN¥1.07 Billion | -0.04% |
| 2008-12-31 | CN¥1.07 Billion | +24.96% |
| 2007-12-31 | CN¥854.65 Million | -36.59% |
| 2006-12-31 | CN¥1.35 Billion | +44.40% |
| 2005-12-31 | CN¥933.43 Million | +72.50% |
| 2004-12-31 | CN¥541.10 Million | -19.15% |
| 2003-12-31 | CN¥669.25 Million | +5.48% |
| 2002-12-31 | CN¥634.50 Million | +51.29% |
| 2001-12-31 | CN¥419.39 Million | +44.11% |
| 2000-12-31 | CN¥291.03 Million | +9.99% |
| 1999-12-31 | CN¥264.61 Million | +27.88% |
| 1998-12-31 | CN¥206.93 Million | -- |